Pfizer, AbbVie resolve IP matters for adalimumab biosimilar
Pfizer adalimumab biosimilar update : Pfizer and AbbVie have signed licensing agreements to resolve all global intellectual property (IP) matters pertaining to the former’s proposed ... Read More